ZW27941 enhanced the efficacy of other therapeutic agents used for acute myeloid leukemia treatment. (IMAGE)
Caption
Drug dose matrix and synergy landscapes of human MV4.11 (A) and MOLM13 (B) cells treated with increasing concentrations of ZW27941, venetoclax, or their combinations for 72 h. Cell viability was evaluated using the CCK-8 assay. The presented results are representative of three independent experiments. The matrix illustrates the percentage of inhibition of treated cells versus vehicle controls. Drug combination landscapes were built using the bioconductor package “synergyfinder".
Credit
Genes & Diseases
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND